Immunity of the placenta and newborns

Recruiting

• Conditions: neonatale immuunontwikkeling; immunsuppressive therapy during pregnancy; 10010273

• Registration Number: NL-OMON44239
• Lead Sponsor: Kindergeneeskunde, Radboudumc

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 80

Inclusion Criteria

Healthy pregnant women aged 18-40 years.;Kidney transplant >1 year before pregnancy
Stable kidney function glomerular filtration rate of >30ml/min/1.73m2

Exclusion Criteria

Healthy:
Use of immunosuppressive drugs, biological or antidepressants
HIV positivity
Active infection during caesarean section
o Signs of infection (maternal fever or signs of intrauterine infection)
o Use of antibiotics prior to caesarean section;Patients
Use of other medication (biologicals or antidepressants) besides immunosuppressive medication
HIV positivity
Active infection during delivery
o Signs of infection (maternal fever or signs of intrauterine infection)
o Use of antibiotics prior to caesarean section

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>1. To investigate the influence of different immunosuppressive drugs on the<br /><br>immune response of placental derived mononuclear cells, peripheral blood<br /><br>derived mononuclear cells, and cord blood derived mononuclear cells.<br /><br><br /><br>2. To investigate the neonatal immune response against a variety of pathogens<br /><br>and compare this with the adult immune response</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>na</p><br>